Get the Stockscreener App
2.05
1.99%
0.04
After Hours:
2.05
Adagene Inc Adr stock is traded at $2.05, with a volume of 48,263.
It is up +1.99% in the last 24 hours and up +7.33% over the past month.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
See More
Previous Close:
$2.01
Open:
$2.05
24h Volume:
48,263
Relative Volume:
0.57
Market Cap:
$90.31M
Revenue:
$18.11M
Net Income/Loss:
$-18.95M
P/E Ratio:
-4.6857
EPS:
-0.4375
Net Cash Flow:
-
1W Performance:
+3.54%
1M Performance:
+7.33%
6M Performance:
-31.89%
1Y Performance:
-37.50%
1-Day Range:
$2.00
$2.06
1-Week Range:
$1.96
$2.27
52-Week Range:
$1.64
$3.5807
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
2.05 | 90.31M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-25-21 | Initiated | China Renaissance | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
Adagene Inc Adr Stock (ADAG) Latest News
Adagene Inc. to Initiate Phase 2 Trial of ADG126 for Colorectal Cancer with Enrollment Starting in April 2025 - Nasdaq
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewswire
Could This New Colorectal Cancer Trial Change Pre-Surgery Treatment? Adagene Tests ADG126 - StockTitan
Head to Head Analysis: Rafael (NYSE:RFL) versus Adagene (NASDAQ:ADAG) - Defense World
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 50.2% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World
Morgan Stanley Downgrades Adagene (NASDAQ:ADAG) to Equal Weight - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene (NASDAQ:ADAG) Cut to “Equal Weight” at Morgan Stanley - Defense World
FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat
HC Wainwright Estimates Adagene FY2029 Earnings - MarketBeat
Morgan Stanley Downgrades Adagene to Equal Weight From Overweight -January 31, 2025 at 07:57 am EST - Marketscreener.com
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Adagene Reports Promising Results in Colorectal Cancer Study - TipRanks
FY2029 Earnings Forecast for Adagene Issued By HC Wainwright - Defense World
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
Adagene (NASDAQ:ADAG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright lifts Adagene stock target to $8 on ASCO data - Investing.com
Adagene reports positive colorectal cancer trial results - Investing.com India
ADAGAdagene Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - The Manila Times
Adagene's Muzastotug Shows 33% Response Rate in Colorectal Cancer Trial - StockTitan
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Adagene to present new ADG126 clinical data at ASCO-GI By Investing.com - Investing.com Australia
Adagene to Announce Updated Data from Phase 1b/2 Study of - GlobeNewswire
Adagene to Present New ADG126-KEYTRUDA Combo Data for Colorectal Cancer at ASCO GI Symposium - StockTitan
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024, Business Wires News - AsiaOne
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025 - Wahanariau
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 - GlobeNewswire
Adagene Hosts Expert Panel on Breakthrough Cancer Treatment ADG126 for Colorectal Cancer - StockTitan
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Short Interest in Adagene Inc. (NASDAQ:ADAG) Increases By 88.2% - MarketBeat
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Fmr LLC Has $2.84 Million Stock Holdings in Adagene Inc. (NASDAQ:ADAG) - Defense World
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Short Interest in Adagene Inc. (NASDAQ:ADAG) Drops By 87.8% - Defense World
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Anheuser-Busch InBev S.A. ADR falls Monday, underperforms market - MSN
Algorae Pharmaceuticals Streamlines Operations with OTCQB Exit - MSN
Adagene Inc Adr Stock (ADAG) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):